Japan's efforts to cut drug costs have prompted at least one big deal this past year, with Takeda Pharmaceutical saying that it would team up with Teva Pharmaceutical Industries to respond to the country's generics push. These kind of deals will become more common, some analysts say, as Japan shifts away from branded meds and spurs development of low-cost copycats.
It's bad news for Purdue Pharma but good news for generics makers such as Teva Pharmaceutical Industries. A federal appeals court affirmed a lower court's decision to toss out some Purdue's patents for its top-selling pain drug OxyContin, further opening the door to cheap knockoff versions of the med.
Teva Pharmaceuticals' efforts to cut costs by making its manufacturing more efficient have landed at a plant in the U.K. where the generics leader will cut dozens of jobs but add some new positions with more specialized skills.
Mapi Pharma has set the terms for its latest crack at listing on Nasdaq. The biotech, which set terms on its first IPO attempt back in April 2014, is aiming to round up around $50 million (€46 million) to bankroll development of its once-a-month version of Teva's blockbuster Copaxone.
The independent company being created by a joint venture between Israel's Teva Pharmaceutical Industries and Japan's Takeda Pharmaceutical became a bit more clear this week when the two pharma giants released additional details on their plans.
An FDA advisory panel has handed Teva a ringing endorsement for its IL-5 asthma drug reslizumab, offering a unanimous recommendation for marketing approval. That recommendation should quickly put it in direct rivalry with GlaxoSmithKline, with AstraZeneca as well as Regeneron following up to compete for command of a new wrinkle in the multibillion-dollar asthma field.
Eight months after Teva scooped up the promising SD-809 (deutetrabenazine) to correct a severe movement disorder afflicting some 500,000 patients in the U.S., the company has scored bragging rights to the FDA's breakthrough drug designation.
Getting patients to stick to their meds is a big problem in treating pulmonary diseases. So to boost adherence for its respiratory portfolio, Teva Pharmaceuticals is turning to technology.
Having tried and failed twice to pull off an IPO on Nasdaq, Israeli biopharma Mapi Pharma has arrived on Wall Street yet again in pursuit of $57.5 million (€51.2 million) to funnel into development of its once-a-month version of Teva's Copaxone.
AbbVie escaped the wrath of the FTC in a pay-for-delay suit over AndroGel generics, as a federal judge who previously threw out antitrust claims against the company rejected the agency's attempts to reconsider its case.